Cancer Genetics (CGIX) Stock Price, News & Analysis

Company Overview

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

Key Stats

• Today's Range: $0.18 to $0.20
• 50-Day Range: $0.15 to $4.61
• 52-Week Range: $2.11 to $17.50
• Volume: 19,116 shs
• Average Volume: 2.44 million shs
• Market Capitalization: $792,490.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CGIX
• CIK: N/A
• Web: www.cancergenetics.com
• Phone: (201) 479-1357
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.33 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,085,000
• Free Float: N/A
• Market Cap: $792,490.00
• Optionable: Not Optionable
• Beta: 2.72